Showing posts with label hiv infection. Show all posts
Showing posts with label hiv infection. Show all posts

This content was generated via a Google Alert and the content is owned by the original site


Click here to visit the original site


 


“Scientists hail discovery of ‘game-changer’ that cuts the risk of infection among gay men by 86%,” The Independent reports. The drug, Truvada, has proved very successful in a “real-world” trial involving 545 participants.


 


Truvada is currently used as part of a treatment plan for people with HIV. It stops the virus from replicating, which helps protect the immune system.


 


Researchers wanted to see if it could also prevent the infection taking hold in the first place and have now presented initial results at a conference.


 


They recruited gay men, other men who have sex with men (MSM) and transgender women who were HIV negative and at high risk of HIV infection from 13 sexual health clinics in England. They randomly assigned them to either immediately start taking Truvada each day, or to wait and start taking it 12 months later.


 


The researchers also wanted to see if taking the medication made people more likely to increase their sexual risk-taking behaviour because they thought they were protected.


 


It is reported that both groups had the same rate of other sexually transmitted infections (STIs), an indication that sexual risk-taking did not change. The incidence of HIV infection in their first year of the study was much smaller in the Truvada group, at three people compared to 19 in the group who had to wait for a year before starting taking Truvada.


 


The researchers plan to submit the study to a peer-reviewed journal in April and are working with a range of stakeholders to determine whether a Truvada service could be commissioned across the NHS for high-risk individuals.



Where did the story come from?


The study was carried out by researchers from the Medical Research Council Clinical Trials Unit at University College London, Public Health England and 12 NHS trusts across England. It was co-funded by the Medical Research Council and Public Health England.


 


The results of the study were presented at the Conference on Retroviruses and Opportunistic Infections in Seattle, Washington. The study has not yet been published, so has not gone through external peer review to ensure the methodology and findings are reliable. The Medical Research Council reports that the study will be submitted to a peer-reviewed journal in April.


 


As the study has not yet been published, this article is based on the information so far released from the Medical Research Council and Public Health England.


 


Most of the UK media’s reporting of the study is accurate. An exception to this is the headline from The Daily Telegraph – “HIV drug taken before and after sex cuts risk by 86pc“, which is misleading as it implies that Truvada could be taken like a morning after pill, but this has not been tested.


 


It is highly likely that taking it in this manner would not be effective.


 


 


What kind of research was this?


This was a randomised controlled trial that aimed to see if Truvada was effective in reducing the incidence of HIV infection in gay and other MSM, and trans-women.


 


The use of drugs such as Truvada to prevent infection, rather than treat infection, is known as Pre-Exposure Prophylaxes (PrEP). Truvada is an anti-retroviral (anti-HIV) drug, which is usually used to treat HIV. It contains two antiviral compounds called emtricitabine and tenofovir disoproxil fumarate. The drug is taken once a day. Anti-retrovirals work by stopping the virus replicating in the body, allowing the immune system to repair itself and preventing further damage. They have proved very successful, though resistance can be a problem, so people with HIV are usually required to take a combination of drugs.


 


Truvada has already been shown to be effective in reducing the incidence of HIV infection compared to placebo (dummy pill). The purpose of this study was to see if taking Truvada changed sexual risk-taking behaviour, by making people feel that they were less likely to be infected and thus increasing their exposure to HIV.


 


This kind of research is important because among gay men, MSM, and trans-women in the UK the rate of HIV infection remains high at 2,800 in 2013.


 


 


What did the research involve?


The researchers recruited 545 gay men, MSM, and trans-women who were HIV negative into the PROUD study (Pre-exposure Option for reducing HIV in the UK: immediate or Deferred). The participants were randomly assigned to have Truvada immediately (N=276) or to wait and have it after 12 months (N=269).


 


The participants were recruited from 13 sexual health clinics in England between November 2012 and April 2014. People were eligible to be included in the study if they had reported having anal sex without a condom in the previous three months and planned to do so again in the near future. This put them in the very high risk category.


 


Participants in both groups were advised to continue other risk prevention strategies such as condom use. They were also asked to keep a short diary, fill out a monthly questionnaire and attend a clinic appointment every three months.


 


 


What were the basic results?


Those taking Truvada were 86% less likely to be infected with HIV:


    • HIV infection occurred in three people taking Truvada compared to 19 in the group who had to wait for a year.

     


      • The infection rate in the Truvada group was 1.3 people infected per 100 people followed up for one year (100 person-years).

       


        • The infection rate in the waiting group was 8.9 per 100 person-years.

         


        Sexual risk-taking behaviour was judged not to have increased in the Truvada group as there was no difference between the groups in terms of the number of participants who had a sexually transmitted infection (STI).


         


        No results were provided from the diaries or questionnaires.


         


         


        How did the researchers interpret the results?


        The chief investigator of the study, Sheena McCormack, is reported to have said: “These results are extremely exciting and show PrEP is highly effective at preventing HIV infection in the real world.” They are now working with a range of stakeholders to determine whether a PrEP service could be commissioned across the NHS.


         


         


        Conclusion


        The results of this unpublished study were presented at a conference in Seattle and have been reported by the Medical Research Council, who helped fund it. As it has not been published, some important details are not yet known, such as:


          • The researchers report that there was “high adherence” to taking the medication, but it is not known how regularly it was taken, or how many people stopped taking it and why.

           


            • No details have been provided about any side effects experienced on the medication.

             


              • The incidence of STIs was used to determine whether taking Truvada changed sexual risk-taking behaviour. It is currently unclear which STIs were compared between the two groups. Three common STIs are viral (genital herpes, genital warts and human papilloma virus), so it is possible that the Truvada reduced their incidence in addition to HIV. This could be an added bonus, but we will need to await publication of the study to look at this.

               


              A limitation of the study is the amount of contact the participants had with the sexual health clinics. They were asked to fill out monthly questionnaires and attend a clinic every three months. It is possible this frequent contact with services caused this particular group to be more aware of the risks of HIV infection.


               


              The researchers plan to submit the study to a peer-reviewed journal in April. In the meantime, they are working with a range of stakeholders to determine whether a PrEP service could be commissioned across the NHS. It has been suggested that men may wish to take PrEP during periods in their life when their sexual risk is highest, rather than continuously. This will no doubt be among the many considerations that will be taken into account.


               


              In conclusion, the researchers report that PrEP reduced HIV infection by 86% in this very high risk group when it was taken on a daily basis. Full publication of this study, and any further developments, are awaited.


               


              The most effective method of reducing your risk of HIV if you are sexually active – and whether you are gay, bisexual, trans or straight, is to always use a condom.


              Sexually transmitted infections (STIs) can pose a serious threat to your sexual health, not to mention your overall wellbeing. But how do you know if an STI has affected your wellness? The Mayo Clinic warns, ‘You could have an STI and be asymptomatic — without any signs or symptoms. In fact, this happens with a lot of STIs. Even though you have no symptoms, you’re still at risk of passing the infection along to your sex partners. That’s why it’s important to use protection, such as a condom, during sex. And visit your doctor on a regular basis for STI screening, so you can identify a potential infection and get treated for it before passing it along to someone else.’ However, some STIs do appear with certain symptoms. So what do you watch out for?


               


              1. Chlamydia: According to the Mayo Clinic, ‘Chlamydia is a bacterial infection of your genital tract. Chlamydia may be difficult for you to detect because early-stage infections often cause few or no signs and symptoms. When they do occur, they usually start one to three weeks after you’ve been exposed to chlamydia. Even when signs and symptoms do occur, they’re often mild and passing, making them easy to overlook.’ The signs and symptoms of chlamydia include:


              • Painful urination

              • Lower abdominal pain

              • Vaginal discharge in women

              • Discharge from the penis in men

              • Pain during sexual intercourse in women

              • Testicular pain in men

               


              2. Gonorrhoea: ‘Gonorrhoea is a bacterial infection of your genital tract,’ the Mayo Clinic explains. ‘The first gonorrhoea symptoms generally appear within two to 10 days after exposure. However, some people may be infected for months before signs or symptoms occur.’ You may have developed gonorrhoea if you experience:


              • Thick, cloudy or bloody discharge from the penis or vagina

              • Pain or burning sensation when urinating

              • Abnormal menstrual bleeding

              • Painful, swollen testicles

              • Painful bowel movements

              • Anal itching

               


              3. Trichomoniasis: The Mayo Clinic details, ‘Trichomoniasis is a common STI caused by a microscopic, one-celled parasite called Trichomonas vaginalis. This organism spreads during sexual intercourse with someone who already has the infection. The organism usually infects the urinary tract in men, but often causes no symptoms in men. Trichomoniasis typically infects the vagina in women. When trichomoniasis causes symptoms, they may range from mild irritation to severe inflammation.’ Signs and symptoms may include:


              • Clear, white, greenish or yellowish vaginal discharge

              • Discharge from the penis

              • Strong vaginal odour

              • Vaginal itching or irritation

              • Itching or irritation inside the penis

              • Pain during sexual intercourse

              • Painful urination

               


              4. HIV: ‘HIV is an infection with the human immunodeficiency virus,’ the Mayo Clinic notes. ‘HIV interferes with your body’s ability to effectively fight off viruses, bacteria and fungi that cause disease, and it can lead to AIDS, a chronic, life-threatening disease. When first infected with HIV, you may have no symptoms at all. Some people develop a flu-like illness, usually two to six weeks after being infected…These early signs and symptoms usually disappear within a week to a month and are often mistaken for those of another viral infection. During this period, you are very infectious.’ The early HIV signs and symptoms may include:


              • Fever

              • Headache

              • Sore throat

              • Swollen lymph glands

              • Rash

              • Fatigue

               


              The Mayo Clinic points out, ‘More persistent or severe symptoms of HIV infection may not appear for 10 years or more after the initial infection. As the virus continues to multiply and destroy immune cells, you may develop mild infections or chronic signs and symptoms.’ These include:


              • Swollen lymph nodes — often one of the first signs of HIV infection

              • Diarrhoea

              • Weight loss

              • Fever

              • Cough and shortness of breath

               


              The signs and symptoms of later stage HIV infection include:


              • Persistent, unexplained fatigue

              • Soaking night sweats

              • Shaking chills or fever higher than 100.4 F (38 C) for several weeks

              • Swelling of lymph nodes for more than three months

              • Chronic diarrhoea

              • Persistent headaches

              • Unusual, opportunistic infections

               

              Although the ultimate goal of AIDs therapy is to prevent the HIV affecting anyone’s sexual health in the first place, so far nothing — from vaccines to gels — has proven up to the task. Still, that’s not to say that drugs haven’t controlled the spread of HIV, but now a new exciting study, published in the New England Journal of Medicine, has found a way for antiretroviral drugs to do the job for which they were always intended: guarding the wellbeing of healthy, uninfected individuals against HIV.


               


              For the study, the researchers investigated almost 2,500 HIV-negative gay men, across six countries, who were at high risk of contracting HIV. Of those participants, some were given the currently prescribed treatment dose of a combination anti-HIV medication known as Truvada, while others took a placebo. After the study’s longest follow up of nearly three years, the researchers found that those taking the medication had a 44% lower rate of HIV infection than those taking a placebo. The benefit was even greater amongst those participants who took their medications more faithfully on a daily basis, as their risk of acquiring HIV dropped to a 73% lower rate than the placebo group.


               


              In a statement, Dr. Kevin Fenton, director of the Centres for Disease Control (CDC) National Centre for HIV-AIDS, Viral Hepatitis, STD and TB Prevention, commented, ‘These results represent a major advance in HIV prevention research. For the first time, we have evidence that a daily pill used to treat HIV is partially effective for preventing HIV among gay and bisexual men at high risk for infection.’ Other wellness experts echoed this excitement, as those in the HIV community have long been pushing for a stronger preventative strategy, especially in the developing world. Dr. Anthony Fauci, director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, noted, ‘The study is really quite impressive, and the data are very robust, really strong.’


               


              The data was particularly encouraging to Fauci, as it represents a closer look at the difference in HIV infection rates among those taking medications, suggesting that varying degrees of exposure to anti-HIV medications can help to thwart infection. Even the volunteers who weren’t on-the-ball with taking their medications had a 13-fold lower rate of HIV infection than those who showed no measurable level of drug in their system. Fauci explained, ‘This is really huge; this is a very impressive result. As with any new treatment strategy, it’s all about whether you adhere to the regimen.’ Fauci added that he suspects many doctors already prescribe antiretroviral medications for this reason; heading off in uninfected but high-risk individuals. Even though government health officials are yet decide whether the results are robust enough to justify recommending anti-HIV drugs as a prevention strategy, Fauci believes these findings should bolster that practice.


               


              Still, that is not to say that the findings give you an excuse to abandon safe sex with condoms. The drugs don’t alter your immune system or prime your body in the same way that a vaccine would against HIV; they act only when the infection is present, and block its ability to infect and replicate in your body’s healthy cells. Therefore, this prevention strategy only ensures that the drugs are on the front lines, ready to act at the first encounter with the virus. As Fenton concluded, ‘[The] results are exciting, but it is not time for anyone to stop using condoms or stop following proven prevention methods. [The study] cannot be seen as the first line of defence against HIV.’